CRDF - Cardiff Oncology's onvansertib may overcome Zytiga resistance in prostate cancer

New efficacy data from ongoing Phase 2 trial of Cardiff Oncology's (CRDF) onvansertib in combination with J&J's Zytiga (abiraterone) and prednisone for metastatic castration-resistant prostate cancer, achieves the primary endpoint of disease control in patients showing initial resistance to J&J's Zytiga (abiraterone).8 of 26 (31%) evaluable patients achieved the primary endpoint of disease control (defined by a lack of prostate specific antigen progression) after 12 weeks of treatment, and 14 of 26 patients had stable disease ((SD)).8 of 26 evaluable patients had durable SD of more than 7 months.Of 8 patients harboring AR alterations associated with Zytiga resistance, 3 achieved disease control at 12 weeks, 4 had SD at 12 weeks and 3 had durable SD (>7 months).Safety was demonstrated across all three different dose and dosing schedule cohorts, as well as the potential clinical benefit for patients with the basal molecular tumor subtype.In February this year, interim results from a Phase 2 trial evaluating onvansertib, combined with J&J's Zytiga

For further details see:

Cardiff Oncology's onvansertib may overcome Zytiga resistance in prostate cancer